TY  - JOUR
AU  - Rahbar, Kambiz
AU  - Essler, Markus
AU  - Eiber, Matthias
AU  - la Fougère, Christian
AU  - Prasad, Vikas
AU  - Fendler, Wolfgang P
AU  - Rassek, Philipp
AU  - Hasa, Ergela
AU  - Dittmann, Helmut
AU  - Bundschuh, Ralph A
AU  - Pabst, Kim M
AU  - Kurtinecz, Milena
AU  - Schmall, Anja
AU  - Verholen, Frank
AU  - Sartor, Oliver
TI  - 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study).
JO  - Journal of nuclear medicine
VL  - 64
IS  - 12
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2023-02059
SP  - 1925-1931
PY  - 2023
N1  - 2023 Dec 1;64(12):1925-1931
AB  - 223Ra-dichloride (223Ra) and 177Lu-prostate-specific membrane antigen (PSMA) are approved treatments for metastatic castration-resistant prostate cancer (mCRPC). The safety and effectiveness of sequential use of 223Ra and 177Lu-PSMA in patients with mCRPC are not well described. This study aimed to evaluate 177Lu-PSMA safety and efficacy in patients with mCRPC previously treated with 223Ra. Methods: The radium→lutetium (RALU) study was a multicenter, retrospective, medical chart review. Participants had received at least 1 223Ra dose and, in any subsequent therapy line, at least 1 177Lu-PSMA dose. Primary endpoints included the incidence of adverse events (AEs), serious AEs, grade 3-4 hematologic AEs, and abnormal laboratory values. Secondary endpoints included overall survival, time to next treatment/death, and change from baseline in serum prostate-specific antigen and alkaline phosphatase levels. Results: Data were from 133 patients. Before 177Lu-PSMA therapy, 56
KW  - 177Lu-PSMA (Other)
KW  - 223Ra (Other)
KW  - metastatic castration-resistant prostate cancer (Other)
KW  - real-world practice (Other)
KW  - targeted α-therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37827838
DO  - DOI:10.2967/jnumed.123.266125
UR  - https://inrepo02.dkfz.de/record/284658
ER  -